Biogen passes FDA test for Alzheimer's medicine
The FDA has approved Biogen's Alzheimer's drug, aducanumab.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Pharmaceutical company Biogen's share prices are increasing rapidly on the US stock exchange after the US health authority, the Food and Drug Administration (FDA), approved its Alzheimer's medication on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Fate of Biogen’s stock rides on Alzheimer’s drug decision
For subscribers
Eli Lilly lowers guidance for 2021
For subscribers
Analysts lose confidence in Biogen Alzheimer's approval
For subscribers
